Japanese drug major Astellas Pharma (TYO: 4503) has launched DigiTx Partners, a digital health investment company in partnership with MPM Capital.
DigiTx Partners will invest in the digital health space broadly, with a special focus on companies which create solutions that improve patient outcomes and provide substantial synergy with a broader pharma business. Although the emphasis will be on earlier stage companies, investments will be made in both start-ups and growth stage companies.
“Exploring unprecedented medical solutions by leveraging Astellas’ strengths in the innovative drug business and integrating these strengths with various medical and healthcare areas is one of the important initiatives of our “Creating Innovation” strategy as part of Astellas Strategic Plan. Through the investment activities of DigiTx Partners, we will explore the business opportunities in the growing field of digital health and extend our knowledge in the area. We look forward to supporting those companies with technologies that will deliver innovative solutions impacting patients’ healthcare and wellness,” said Kenji Yasukawa, senior vice president and chief strategy officer, Astellas.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze